{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443854261
| IUPAC_name = 4-(2-Chlorophenyl)-2-ethyl-9-methyl-6''H''-thieno[3,2-''f''][1,2,4]triazolo[4,3-''a''][1,4]diazepine
| tradename = Etilaam, Etizest
| image = Etizolam.svg
| width = 150
| image2= EtizXtal3.png 
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01514
| ChemSpiderID = 3191
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| smiles = ClC1=CC=CC=C1C2=NCC3=NN=C(C)N3C4=C2C=C(CC)S4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VMZUTJCNQWMAGF-UHFFFAOYSA-N
| UNII = A76XI0HL37
| UNII_Ref = {{fdacite|correct|FDA}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number=40054-69-1
| ATC_prefix=N05
| ATC_suffix=BA19
| ATC_supplemental =
| PubChem = 3307
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1289779
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank=
| C=17 | H=15 | Cl=1 | N=4 | S=1
| molecular_weight = 342.07 g/mol
| bioavailability= 93%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 6.2 hours<ref name=depas>{{cite web |url=http://www.carloanibaldi.com/terapia/schede/DEPAS.htm |title=Depas |accessdate=October 31, 2015}}</ref>
(main metabolite is 8.2 hours)
| excretion = [[Kidney|Renal]]
| pregnancy_category =
| legal_DE = Anlage III<!-- | legal_DK = Controlled| legal_JP = Restricted Analog -->
| legal_US = Schedule I
| legal_US_comment =  in Alabama, Arkansas, Florida, Mississippi, and Virginia; Schedule IV in Georgia; Scheduled in Arizona<ref>http://legiscan.com/AZ/research/HB2033/2017</ref> and Indiana;<ref name="indianahouserepublicans.com">http://www.indianahouserepublicans.com/news/press-releases/ellington-s-bill-banning-two-deadly-drugs-could-soon-be-law/</ref> not FDA approved. Unscheduled in the remaining states.
| legal_UK = Class C
| dependency_liability = Moderate
| routes_of_administration= Oral, sublingual, rectal
|drug_name=|alt=|caption=|type=|MedlinePlus=|legal_status=|licence_EU=|pregnancy_AU=|pregnancy_US=|licence_US=}}

'''Etizolam''' (marketed under the brand name '''Etilaam''', '''Etizola''', '''Sedekopan''', '''Etizest''', '''Pasaden''' or '''Depas''') is a [[benzodiazepine]] analog. The etizolam molecule differs from a benzodiazepine in that the [[benzene]] ring has been replaced by a [[thiophene]] ring and [[triazole]] ring has been fused, making the drug a [[thienotriazolodiazepine]].<ref>{{cite journal |vauthors=Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A |title=Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs |journal=Biol. Pharm. Bull. |volume=28 |issue=9 |pages=1711–6 |date=September 2005 |pmid=16141545 |doi= 10.1248/bpb.28.1711|url=http://www.jstage.jst.go.jp/article/bpb/28/9/1711/_pdf |format=PDF}}</ref><ref>{{cite journal|last1=Catabay|first1=A.|last2=Taniguchi|first2=M.|last3=Jinno|first3=K.|last4=Pesek|first4=J. J.|last5=Williamsen|first5=E.|title=Separation of 1,4-Benzodiazepines and Analogues Using Cholesteryl-10-Undecenoate Bonded Phase in Microcolumn Liquid Chromatography|journal=Journal of Chromatographic Science|date=1 March 1998|volume=36|issue=3|page=113|doi=10.1093/chromsci/36.3.111}}<!--|accessdate=3 December 2015--></ref> It possesses [[amnesic]], [[anxiolytic]], [[anticonvulsant]], [[hypnotic]], [[sedative]] and [[skeletal muscle relaxant]] properties.<ref>{{cite journal |vauthors=Mandrioli R, Mercolini L, Raggi MA |title=Benzodiazepine metabolism: an analytical perspective |journal=Curr. Drug Metab. |volume=9 |issue=8 |pages=827–44 |date=October 2008 |pmid=18855614 |doi=10.2174/138920008786049258 |url=http://www.benthamdirect.org/pages/content.php?CDM/2008/00000009/00000008/0009F.SGM |deadurl=yes |archiveurl=https://web.archive.org/web/20090317092123/http://www.benthamdirect.org/pages/content.php?CDM%2F2008%2F00000009%2F00000008%2F0009F.SGM |archivedate=2009-03-17 |df= }}</ref>

==Indications==
* Short-term treatment of [[insomnia]]<ref>{{cite journal |vauthors=Lopedota A, Cutrignelli A, Trapani A |title=Effects of different cyclodextrins on the morphology, loading and release properties of poly (DL-lactide-co-glycolide)-microparticles containing the hypnotic agent etizolam |journal=J Microencapsul |volume=24 |issue=3 |pages=214–24 |date=May 2007 |pmid=17454433 |doi=10.1080/02652040601058152 |url=|display-authors=etal}}</ref>
* Short-term treatment of [[anxiety]] or [[panic attack]]s, if a benzodiazepine is required<ref name=depas />

==Side effects==
* [[Blepharospasm]]s with long-term use<ref>{{cite journal |vauthors=Wakakura M, Tsubouchi T, Inouye J |title=Etizolam and benzodiazepine induced blepharospasm |journal=J. Neurol. Neurosurg. Psychiatr. |volume=75 |issue=3 |pages=506–7 |date=March 2004 |pmid=14966178 |pmc=1738986 |doi= 10.1136/jnnp.2003.019869}}</ref>

'''Very Rare'''
* [[Erythema annulare centrifugum]] skin lesions<ref>{{cite journal |vauthors=Kuroda K, Yabunami H, Hisanaga Y |title=Etizolam-induced superficial erythema annulare centrifugum |journal=Clin. Exp. Dermatol. |volume=27 |issue=1 |pages=34–6 |date=January 2002 |pmid=11952667 |doi= 10.1046/j.0307-6938.2001.00943.x|url=}}</ref>

==Tolerance, dependence and withdrawal==
Abrupt or rapid discontinuation from etizolam, as with [[benzodiazepines]], may result in the appearance of the [[benzodiazepine withdrawal syndrome]], including [[rebound insomnia]].<ref>{{cite journal |vauthors=Hirase M, Ishida T, Kamei C |title=Rebound insomnia induced by abrupt withdrawal of hypnotics in sleep-disturbed rats |journal=Eur. J. Pharmacol. |volume=597 |issue=1–3 |pages=46–50 |date=November 2008 |pmid=18789918 |doi=10.1016/j.ejphar.2008.08.024 |url=}}</ref> [[Neuroleptic malignant syndrome]], a rare event in benzodiazepine withdrawal, has been documented in a case of abrupt withdrawal from etizolam.<ref>{{cite journal |vauthors=Kawajiri M, Ohyagi Y, Furuya H |title=[A patient with Parkinson's disease complicated by hypothyroidism who developed malignant syndrome after discontinuation of etizolam] |language=Japanese |journal=Rinsho Shinkeigaku |volume=42 |issue=2 |pages=136–9 |date=February 2002 |pmid=12424963 |doi= |url=|display-authors=etal}}</ref> This is particularly relevant given etizolam's short half life relative to benzodiazepines such as [[diazepam]] resulting in a more rapid drug level decrease in blood plasma levels.<ref>http://www.annualreviews.org/doi/abs/10.1146/annurev.me.36.020185.002225?journalCode=med</ref>

In a study that compared the effectiveness of etizolam, [[alprazolam]], and [[bromazepam]] for the treatment of [[generalized anxiety disorder]], all three drugs retained their effectiveness over 2 weeks, but etizolam became more effective from 2 weeks to 4 weeks, a type of reverse tolerance.<ref>{{cite journal | pmid = 2572494 | year = 1989 | last1 = Bertolino | first1 = A | last2 = Mastucci | first2 = E | last3 = Porro | first3 = V | last4 = Corfiati | first4 = L | last5 = Palermo | first5 = M | last6 = Ecari | first6 = U | last7 = Ceccarelli | first7 = G | title = Etizolam in the treatment of generalized anxiety disorder: A controlled clinical trial | volume = 17 | issue = 5 | pages = 455–60 | journal = The Journal of international medical research}}</ref>  Administering .5&nbsp;mg etizolam twice daily did not induce cognitive deficits over 3 weeks when compared to placebo.<ref>{{cite journal | pmid = 20110024 | year = 2009 | last1 = De Candia | first1 = MP | last2 = Di Sciascio | first2 = G | last3 = Durbano | first3 = F | last4 = Mencacci | first4 = C | last5 = Rubiera | first5 = M | last6 = Aguglia | first6 = E | last7 = Garavini | first7 = A | last8 = Bersani | first8 = G | last9 = Di Sotto | first9 = A | last10 = Placidi | first10 = G | last11 = Cesana | first11 = BM | title = Effects of treatment with etizolam 0.5 mg BID on cognitive performance: A 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder | volume = 31 | issue = 12 | pages = 2851–9 | doi = 10.1016/j.clinthera.2009.12.010 | journal = Clinical therapeutics}}</ref>

When multiple doses of etizolam, or [[lorazepam]], were administered to rat neurons, lorazepam caused downregulation of [[GABAA receptor|alpha-1 benzodiazepine binding sites]] (tolerance/dependence), while etizolam caused an increase in alpha-2 benzodiazepine binding sites (reverse tolerance to anti-anxiety effects).<ref name="Missingor">{{cite journal | pmid = 16107249 | year = 2005 | last1 = Sanna | first1 = E | last2 = Busonero | first2 = F | last3 = Talani | first3 = G | last4 = Mostallino | first4 = MC | last5 = Mura | first5 = ML | last6 = Pisu | first6 = MG | last7 = MacIocco | first7 = E | last8 = Serra | first8 = M | last9 = Biggio | first9 = G | title = Low tolerance and dependence liabilities of etizolam: Molecular, functional, and pharmacological correlates | volume = 519 | issue = 1–2 | pages = 31–42 | doi = 10.1016/j.ejphar.2005.06.047 | journal = European Journal of Pharmacology }}</ref>  Tolerance to the anticonvulsant effects of lorazepam was observed, but no significant tolerance to the anticonvulsant effects of etizolam was observed.<ref name="Missingor" /> Etizolam therefore has a reduced liability to induce tolerance, and dependence, compared with classic benzodiazepines.<ref name="Missingor" />

==Pharmacology==
Etizolam, a thienodiazepine derivative, is absorbed fairly rapidly, with peak plasma levels achieved between 30 minutes and 2 hours. It has a mean elimination half life of about 3.5 hours.<ref name="singmultdose">{{cite journal |vauthors=Fracasso C, Confalonieri S, Garattini S, Caccia S |title=Single and multiple dose pharmacokinetics of etizolam in healthy subjects |journal=Eur. J. Clin. Pharmacol. |volume=40 |issue=2 |pages=181–5 |year=1991 |pmid=2065698 |doi= 10.1007/BF00280074}}</ref>  Etizolam possesses potent [[hypnotic]] properties,<ref>{{cite journal |vauthors=Nakamura J, Mukasa H |title=Effects of thienodiazepine derivatives, etizolam and clotiazepam on the appearance of Fm theta |journal=Jpn. J. Psychiatry Neurol. |volume=46 |issue=4 |pages=927–31 |date=December 1992 |pmid=1363923 |doi= 10.1111/j.1440-1819.1992.tb02862.x|url=}}</ref> and is comparable with other short-acting [[benzodiazepine]]s.<ref name="singmultdose"/>  Etizolam acts as a [[full agonist]] at the benzodiazepine receptor to produce its range of therapeutic and adverse effects.<ref>{{cite journal |vauthors=Yakushiji T, Fukuda T, Oyama Y, Akaike N |title=Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones |journal=Br. J. Pharmacol. |volume=98 |issue=3 |pages=735–40 |date=November 1989 |pmid=2574062 |pmc=1854765 |doi=10.1111/j.1476-5381.1989.tb14600.x }}</ref>

According to the Italian P.I. sheet{{Citation needed|date=March 2015}}, etizolam belongs to a new class of [[diazepine]]s, [[thienotriazolodiazepine]]s. This new class is easily [[Oxidize#Redox reactions in biology|oxidized]], rapidly [[Metabolism|metabolized]], and has a lower risk of accumulation, even after prolonged treatment. Etizolam has an [[anxiolytic]] action about 6 times greater than that of [[diazepam]]. Etizolam produces, especially at higher dosages, a reduction in time taken to fall asleep, an increase in total sleep time, and a reduction in the number of awakenings. During tests, there were no substantial changes in [[Slow-wave sleep|deep sleep]]; however, it may reduce [[Rapid eye movement sleep|REM sleep]]. In [[Electroencephalography|EEG]] tests of healthy volunteers, etizolam showed some similar characteristics to [[tricyclic antidepressant]]s.<ref name=depas>{{cite web |url=http://www.carloanibaldi.com/terapia/schede/DEPAS.htm |title=Depas |accessdate=October 31, 2015}}</ref>

==Legal status==

=== Denmark ===
Etizolam is controlled in Denmark under the Danish Misuse of Drugs Act.<ref>{{cite web | url=https://www.retsinformation.dk/Forms/R0710.aspx?id=137169 | title=Bekendtgørelse om euforiserende stoffer | work=retsinformation.dk | accessdate=2016-11-21 | language=Danish}}</ref>

===Germany===
Etizolam was controlled in Germany in July 2013.<ref>http://www.bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/B/Betaeubungsmittelgesetz/27_BtMAEndV.pdf and http://www.gesetze-im-internet.de/btmg_1981/index.html.</ref>

=== Japan ===
Etizolam also called Depas, is restricted as a benzodiazepine analog in Japan from October 2016 onwards.

===United Kingdom===
In the UK, etizolam has been classified as a [[Drugs controlled by the UK Misuse of Drugs Act|Class C drug]] by the May 2017 amendment to [[Misuse of Drugs Act 1971|The Misuse of Drugs Act 1971]] along with several other designer benzodiazepine drugs.<ref>{{Cite web|url=http://www.legislation.gov.uk/uksi/2017/634/contents/made|title=The Misuse of Drugs Act 1971 (Amendment) Order 2017|last=|first=|date=|website=|access-date=}}</ref>

===United States===
Etizolam is not authorized by the FDA for medical use in the U.S. However, it currently remains unscheduled and is legal for research purposes. As of March 2016, etizolam is a controlled substance in the following states: Alabama, Arkansas,<ref>http://www.healthy.arkansas.gov/aboutadh/rulesregs/controlled_substances_list.pdf</ref> Florida,<ref>http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html</ref> Mississippi,<ref>http://billstatus.ls.state.ms.us/documents/2014/html/HB/1200-1299/HB1231SG.htm</ref> Virginia,<ref>{{cite web | url=http://law.lis.virginia.gov/admincode/title18/agency110/chapter20/section322/ | title=18VAC110-20-322. Placement of Chemicals in Schedule I. | publisher=Commonwealth of Virginia | date=2 December 2015 | language=English | accessdate= 11 March 2016}}</ref>Texas, Louisiana and Georgia.<ref>http://www.namsdl.org/library/946E60B2-ABB3-24A6-F087859B3EA48EC1/</ref> It is controlled in Indiana as of July 1, 2017.<ref name="indianahouserepublicans.com">http://www.indianahouserepublicans.com/news/press-releases/ellington-s-bill-banning-two-deadly-drugs-could-soon-be-law/</ref>

==Interactions==
[[Itraconazole]] and [[fluvoxamine]] slow down the rate of elimination of etizolam, leading to accumulation of etizolam, therefore increasing its pharmacological effects.<ref>{{cite journal |vauthors=Araki K, Yasui-Furukori N, Fukasawa T |title=Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism |journal=Eur. J. Clin. Pharmacol. |volume=60 |issue=6 |pages=427–30 |date=August 2004 |pmid=15232663 |doi=10.1007/s00228-004-0789-1|display-authors=etal}}</ref><ref>{{cite journal |vauthors=Suzuki Y, Kawashima Y, Shioiri T, Someya T |title=Effects of concomitant fluvoxamine on the plasma concentration of etizolam in Japanese psychiatric patients: wide interindividual variation in the drug interaction |journal=Ther Drug Monit |volume=26 |issue=6 |pages=638–42 |date=December 2004 |pmid=15570188 |doi= 10.1097/00007691-200412000-00009|url=}}</ref> [[Carbamazepine]] speeds up the metabolism of etizolam, resulting in reduced pharmacological effects.<ref>{{cite journal |vauthors=Kondo S, Fukasawa T, Yasui-Furukori N |title=Induction of the metabolism of etizolam by carbamazepine in humans |journal=Eur. J. Clin. Pharmacol. |volume=61 |issue=3 |pages=185–8 |date=May 2005 |pmid=15776275 |doi=10.1007/s00228-005-0904-y|display-authors=etal}}</ref>

==Overdose==
{{See also|Benzodiazepine overdose}}
Cases of intentional suicide by [[benzodiazepine overdose|overdose]] using etizolam in combination with GABA agonists have been reported.<ref>{{cite journal |vauthors=Nakamae T, Shinozuka T, Sasaki C |title=Case report: Etizolam and its major metabolites in two unnatural death cases |journal=Forensic Sci. Int. |volume=182 |issue=1–3 |pages=e1–6 |date=November 2008 |pmid=18976871 |doi=10.1016/j.forsciint.2008.08.012 |url=|display-authors=etal}}</ref><ref>{{cite journal|first1=Gudrun|last1=Høiseth|first2=Silja Skogstad|last2=Tuv|first3=Ritva|last3=Karinen|title=Blood concentrations of new designer benzodiazepines in forensic cases|url=http://www.sciencedirect.com/science/article/pii/S0379073816304121|journal=Forensic Science International|doi=10.1016/j.forsciint.2016.09.006|date=2016|volume=268|pages=35–38|pmid=27685473}}</ref> Although etizolam has a lower [[Median lethal dose|LD50]] than certain [[benzodiazepines]], the LD50 is still far beyond the prescribed or recommended dose. [[Flumazenil]], a GABA antagonist agent used to reverse benzodiazepine overdoses, inhibits the effect of etizolam as well as classical benzodiazepines such as diazepam and chlordiazepoxide.<ref>{{cite journal |vauthors=Woolverton WL, Nader MA |title=Case report: Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline. |journal=Psychopharmacology |volume=122 |issue=3 |pages=230–236 |date=December 1995 |pmid=8748392 |doi=10.1007/BF02246544 |url=|display-authors=etal}}</ref>

==Abuse==
{{See also|Benzodiazepine misuse}}
Etizolam is a drug of potential abuse. Cases of etizolam dependence have been documented in the medical literature.<ref>{{cite journal |vauthors=Gupta S, Garg B | year = 2014 | title =  A case of etizolam dependence| journal = Indian J Pharmacol | volume = 46 | issue = 6| pages = 655–656 | pmc=4264086 | pmid=25538342 | doi=10.4103/0253-7613.144943}}</ref> However, conflicting reports from the World Health Organization, made public in 1991, dispute the abuse claims.<ref>[http://whqlibdoc.who.int/trs/WHO_TRS_808.pdf WHO Expert Committee on Drug Dependence]</ref>

==See also==
{{colbegin|2}}
* [[Alprazolam]]
* [[Brotizolam]]
* [[Clotiazepam]]
* [[Deschloroetizolam]]
* [[Metizolam]]
* [[Benzodiazepine dependence]]
* [[Benzodiazepine withdrawal syndrome]]
* [[Long-term effects of benzodiazepines]]
{{colend}}

==References==
{{Reflist|30em}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim926.htm Inchem.org - Etizolam]

{{Benzodiazepines}}
{{Anxiolytics}}
{{GABAAR PAMs}}
{{PAF signaling}}

[[Category:Chloroarenes]]
[[Category:Designer drugs]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Hypnotics]]
[[Category:Thienotriazolodiazepines]]